MMP1

Summary

MMP1 (matrix metallopeptidase 1, HGNC:7155) is a protein-coding gene on chromosome 11q22.2, encoding Interstitial collagenase (P03956). Cleaves collagens of types I, II, and III at one site in the helical domain. In precision oncology, MMP1 Overexpression is associated with resistance to Sacituzumab Govitecan in Estrogen Receptor-positive Breast Cancer (CIViC Level D).

This gene encodes a member of the peptidase M10 family of matrix metalloproteinases (MMPs). Proteins in this family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. The encoded preproprotein is proteolytically processed to generate the mature protease. This secreted protease breaks down the interstitial collagens, including types I, II, and III. The gene is part of a cluster of MMP genes on chromosome 11. Mutations in this gene are associated with chronic obstructive pulmonary disease (COPD). Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.

Source: NCBI Gene 4312 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 149 total
• GTEx eGene: eQTL in 21 tissues, sQTL in 0 (q < 0.05)
• Phenotypes (HPO): 58
• Drug target: yes — 3 curated mechanism-of-action drugs; 21 molecules with ChEMBL bioactivity (top 2% of genes corpus-wide)
• Approved drugs (ChEMBL mechanism of action): 1 — Doxycycline
• Precision-oncology evidence (CIViC): 1 curated variant–drug association
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.29 (unconstrained)
• MANE Select transcript: NM_002421
• Interaction hub: 2,770 STRING partners (top 3% of genes corpus-wide)

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7155
Approved symbol	MMP1
Name	matrix metallopeptidase 1
Location	11q22.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000196611
Ensembl biotype	protein_coding
OMIM	120353
Entrez	4312

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 2 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

MANE Select: ENST00000315274

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1

ENST00000315274, ENST00000680179, ENST00000681445, ENST00000681643, ENST00001144079

RefSeq mRNA: 2 — MANE Select: NM_002421 NM_001145938, NM_002421

CCDS: CCDS8322

Canonical transcript exons

ENST00000315274 — 10 exons

Exon	Start	End
ENSE00000993183	102795174	102795291
ENSE00000993195	102792605	102792738
ENSE00000993197	102795452	102795607
ENSE00000993199	102791333	102791495
ENSE00000993204	102790703	102790806
ENSE00000993211	102797256	102797500
ENSE00000993213	102797014	102797162
ENSE00001105440	102796664	102796789
ENSE00001234609	102797988	102798160
ENSE00001234621	102789919	102790521

Expression profiles

Bgee: expression breadth ubiquitous, 172 present calls, max score 99.09.

FANTOM5 (CAGE): breadth broad, TPM avg 239.1385 / max 18368.5720, expressed in 879 samples.

Highest expression (Bgee): epithelial cell of pancreas, pancreatic ductal cell, islet of Langerhans, cartilage tissue, type B pancreatic cell.

Genetic regulation across tissues (GTEx eQTL / sQTL)

MMP1 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 21 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 21 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	eqtl	4.6e-111	-0.71	11:102799764:TC:T
Thyroid	eqtl	2.3e-27	-0.55	11:102799764:TC:T
Heart Atrial Appendage	eqtl	2.4e-26	-0.61	11:102799764:TC:T
Lung	eqtl	6.7e-20	-0.38	11:102799764:TC:T
Heart Left Ventricle	eqtl	5.0e-16	-0.51	11:102799764:TC:T
Adipose Visceral Omentum	eqtl	1.2e-15	-0.43	11:102799764:TC:T
Pancreas	eqtl	1.5e-12	+0.52	11:102792772:T:C
Nerve Tibial	eqtl	3.3e-12	-0.39	11:102799764:TC:T
Adipose Subcutaneous	eqtl	1.0e-10	-0.35	11:102799764:TC:T
Esophagus Muscularis	eqtl	2.9e-10	-0.40	11:102799764:TC:T
Artery Aorta	eqtl	2.2e-07	-0.37	11:102799764:TC:T
Breast Mammary Tissue	eqtl	2.7e-07	-0.36	11:102799764:TC:T
Artery Tibial	eqtl	1.1e-06	-0.26	11:102799764:TC:T
Whole Blood	eqtl	4.2e-05	+0.22	11:102800966:C:T
Skin Sun Exposed Lower leg	eqtl	5.9e-05	+0.47	11:102797955:T:A
Stomach	eqtl	2.3e-03	-0.22	11:102785055:C:T
Skin Not Sun Exposed Suprapubic	eqtl	5.9e-03	+0.79	11:103447989:C:A
Spleen	eqtl	6.4e-03	-0.31	11:102785692:G:A
Artery Coronary	eqtl	1.0e-02	-0.35	11:102799764:TC:T
Testis	eqtl	2.2e-02	-1.30	11:102759812:C:A

FANTOM5 promoters

showing 10 of 24 alternative TSS:

Promoter ID	TPM avg	Samples expressed
122018	231.0513	856
122001	3.1155	283
121998	0.7959	180
121995	0.5200	164
122009	0.4695	162
122012	0.4472	170
122008	0.4334	130
122007	0.2731	109
122011	0.2674	114
122015	0.2650	122

Top tissues by expression

showing 100 of 274 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	99.09	gold quality
pancreatic ductal cell	CL:0002079	98.93	gold quality
islet of Langerhans	UBERON:0000006	98.21	gold quality
cartilage tissue	UBERON:0002418	98.20	gold quality
type B pancreatic cell	CL:0000169	97.71	gold quality
synovial membrane of synovial joint	UBERON:0002018	97.06	gold quality
gall bladder	UBERON:0002110	94.66	gold quality
stromal cell of endometrium	CL:0002255	90.21	gold quality
amniotic fluid	UBERON:0000173	85.31	gold quality
pylorus	UBERON:0001166	83.59	gold quality
decidua	UBERON:0002450	83.35	gold quality
mucosa of urinary bladder	UBERON:0001259	81.56	gold quality
duodenum	UBERON:0002114	81.39	gold quality
jejunal mucosa	UBERON:0000399	79.93	gold quality
palpebral conjunctiva	UBERON:0001812	78.93	gold quality
vermiform appendix	UBERON:0001154	78.27	gold quality
rectum	UBERON:0001052	76.63	gold quality
body of stomach	UBERON:0001161	75.96	gold quality
caecum	UBERON:0001153	75.86	gold quality
mucosa of sigmoid colon	UBERON:0004993	75.50	gold quality
visceral pleura	UBERON:0002401	74.84	gold quality
periodontal ligament	UBERON:0008266	74.37	silver quality
stomach	UBERON:0000945	72.88	gold quality
nasal cavity epithelium	UBERON:0005384	72.01	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	71.10	gold quality
colonic mucosa	UBERON:0000317	70.80	gold quality
colonic epithelium	UBERON:0000397	69.98	gold quality
placenta	UBERON:0001987	68.08	gold quality
pancreas	UBERON:0001264	68.00	gold quality
jejunum	UBERON:0002115	67.73	gold quality
nasal cavity mucosa	UBERON:0001826	66.54	gold quality
monocyte	CL:0000576	66.34	gold quality
mononuclear cell	CL:0000842	66.03	gold quality
mucosa of transverse colon	UBERON:0004991	65.16	gold quality
layer of synovial tissue	UBERON:0007616	64.73	gold quality
leukocyte	CL:0000738	64.71	gold quality
corpus epididymis	UBERON:0004359	64.05	gold quality
spleen	UBERON:0002106	63.21	gold quality
fundus of stomach	UBERON:0001160	62.73	gold quality
small intestine	UBERON:0002108	62.61	gold quality
upper lobe of lung	UBERON:0008948	62.49	gold quality
upper lobe of left lung	UBERON:0008952	62.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	60.42	gold quality
ileal mucosa	UBERON:0000331	60.22	gold quality
smooth muscle tissue	UBERON:0001135	59.50	gold quality
urinary bladder	UBERON:0001255	59.28	gold quality
cauda epididymis	UBERON:0004360	59.12	gold quality
lymph node	UBERON:0000029	58.55	gold quality
gingiva	UBERON:0001828	57.53	gold quality
lung	UBERON:0002048	57.31	gold quality
endometrium epithelium	UBERON:0004811	57.30	gold quality
mucosa of paranasal sinus	UBERON:0005030	55.14	gold quality
transverse colon	UBERON:0001157	54.75	gold quality
intestine	UBERON:0000160	54.57	gold quality
lower esophagus mucosa	UBERON:0035834	53.98	gold quality
minor salivary gland	UBERON:0001830	53.65	gold quality
cervix squamous epithelium	UBERON:0006922	53.51	silver quality
tendon of biceps brachii	UBERON:0008188	53.43	gold quality
mouth mucosa	UBERON:0003729	53.18	gold quality
skin of hip	UBERON:0001554	53.12	silver quality
metanephros cortex	UBERON:0010533	53.11	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	53.09	gold quality
cardia of stomach	UBERON:0001162	52.53	gold quality
hair follicle	UBERON:0002073	52.43	gold quality
adult organism	UBERON:0007023	52.37	gold quality
pleura	UBERON:0000977	52.23	silver quality
metanephros	UBERON:0000081	51.78	gold quality
large intestine	UBERON:0000059	51.76	gold quality
body of pancreas	UBERON:0001150	51.61	gold quality
nephron tubule	UBERON:0001231	51.60	silver quality
cortex of kidney	UBERON:0001225	51.50	gold quality
adult mammalian kidney	UBERON:0000082	50.93	gold quality
colon	UBERON:0001155	50.89	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
gingival epithelium	UBERON:0001949	50.23	silver quality
choroid plexus epithelium	UBERON:0003911	50.21	silver quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
saliva-secreting gland	UBERON:0001044	49.97	gold quality
kidney	UBERON:0002113	49.96	gold quality
quadriceps femoris	UBERON:0001377	49.93	gold quality
thymus	UBERON:0002370	49.73	gold quality
bronchus	UBERON:0002185	49.68	silver quality
vastus lateralis	UBERON:0001379	49.50	gold quality
epithelium of bronchus	UBERON:0002031	49.40	silver quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
tonsil	UBERON:0002372	49.22	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
myocardium	UBERON:0002349	48.87	gold quality
epithelium of nasopharynx	UBERON:0001951	48.64	silver quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality
right uterine tube	UBERON:0001302	48.47	gold quality
metanephric glomerulus	UBERON:0004736	48.46	gold quality
left ventricle myocardium	UBERON:0006566	48.24	gold quality
orbitofrontal cortex	UBERON:0004167	48.20	gold quality
renal glomerulus	UBERON:0000074	48.18	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-10	yes	2840.46
E-MTAB-6308	yes	953.77
E-MTAB-5061	yes	5.93
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

58 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Gallbladder	tissue	70.7
Urinary bladder	tissue	48.6
Appendix	tissue	25.2
Stomach 1	tissue	15.8
Small intestine	tissue	12.2
Endometrium 1	tissue	10.0
Duodenum	tissue	7.5
Placenta	tissue	6.7
Rectum	tissue	6.4
Hippocampal formation	tissue	4.0
Colon	tissue	3.8
Tonsil	tissue	1.5
Lung	tissue	1.3
Smooth muscle	tissue	1.1
Amygdala	tissue	1.1
Skin 1	tissue	0.5
Ovary	tissue	0.5
Substantia nigra	tissue	0.4
Entorhinal cortex	tissue	0.4
Prefrontal cortex	tissue	0.3
Heart muscle	tissue	0.3
Cerebral cortex	tissue	0.3
Adipose tissue	tissue	0.3
Pancreas	tissue	0.3
Motor cortex	tissue	0.3
Kidney	tissue	0.3
Thymus	tissue	0.3
Bone marrow	tissue	0.3
Periaqueductal gray	tissue	0.3
Retrosplenial cortex	tissue	0.3
Insular cortex	tissue	0.3
Vagina	tissue	0.2
Basal ganglia	tissue	0.2
Putamen	tissue	0.2
Hypothalamus	tissue	0.2
Superior colliculi	tissue	0.2
Spleen	tissue	0.2
Spinal cord	tissue	0.2
Corpus callosum	tissue	0.2
Ventral forebrain	tissue	0.2
Retrosplenial and cingulate cortex	tissue	0.2
Olfactory bulb	tissue	0.2
Septum	tissue	0.2
Temporal cortex	tissue	0.2
Cervix	tissue	0.1
Pituitary gland	tissue	0.1
Lymph node	tissue	0.1
Testis	tissue	0.1
Pons	tissue	0.1
Seminal vesicle	tissue	0.1
Midbrain	tissue	0.1
Medulla oblongata	tissue	0.1
Thalamus	tissue	0.1
Liver	tissue	0.1
Locus coeruleus	tissue	0.1
Prostate	tissue	0.1
Somatosensory cortex	tissue	0.1
Occipital cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 16; highest nTPM — Ventral hippocampus (4.0), Dorsal hippocampus (3.5), Area parastriata, superior (3.0), Subiculum (0.9), Lateral hypothalamic area (0.4).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, AP1, AR, ATF2, ATF3, BACH1, BATF3, BCL3, CEBPA, CEBPB, CEBPG, CITED2, COP1, CREB1, CTNNB1, EGR1, EHF, ELF2, ERG, ESR1, ESR2, ETS1, ETS2, ETV1, ETV2, ETV3, ETV4, ETV7, EWSR1, FBN1, FLI1, FOS, FOSL1, FOXN1, FOXO1, FOXO3, GATA3, HIF1A, HOPX, HR

miRNA regulators (miRDB)

Targeting MMP1 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 38 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7F-5P	99.98	72.56	1784
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-3176	99.25	64.35	954
HSA-MIR-3922-3P	99.25	64.96	1136
HSA-MIR-5190	99.15	67.76	1234
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-936	98.87	70.51	1124
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-5094	98.63	67.11	1062
HSA-MIR-518C-5P	98.53	69.20	1640
HSA-MIR-3136-5P	98.53	67.68	793
HSA-MIR-4439	98.53	67.53	793
HSA-MIR-326	98.25	66.44	1565

Functional genomics

gnomAD constraint: pLI 1.39e-15, LOEUF 1.29, missense Z -0.415 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000315274 — one region, missense o/e 1.10.

Literature-anchored findings (GeneRIF, showing 40)

• Patients with detectable concentrations of urinary MMP-1 had higher rates of disease progression and death from bladder cancer than patients with undetectable urinary MMP-1. (PMID:11705862)
• members of the forkhead family of transcription factors play a role in regulation of the collagenase promoter and increased activity of forkhead transcription factors underlie the increase in collagenase expression observed during replicative senescence (PMID:11751876)
• 17beta-estradiol represses MMP-1 synthesis, and this effect may contribute to its action on the inhibition of bone resorption (PMID:11762702)
• role in degradation of extracellular matrix and joint destruction (PMID:11831026)
• induction in fibroblasts by basic calcium phosphate crystals (PMID:11836255)
• These data suggest that polymorphisms in the MMP1 and MMP12 genes, but not MMP9, are either causative factors in smoking-related lung injury or are in linkage disequilibrium with causative polymorphisms (PMID:11875051)
• Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells. (PMID:11918701)
• in the late healing period of radiation-impaired wounds, increased expression of MMP1 may be related to overdegradation of matrixes and difficulty in granulation tissue formation (PMID:11934016)
• A newly identified single nucleotide polymorphism at position -519 in the promoter region of the MMP-1 gene is reported. This polymorphism consists in a guanine to adenine substitution. A linkage between polymorphisms -519A/G and -1607 1G/2G was studied. (PMID:12005449)
• Reduction of cytokine-induced expression and activity of MMP-1 and MMP-13 by mechanical strain in MH7A rheumatoid synovial cells (PMID:12009332)
• Accessory elements, flanking DNA sequence, and promoter context play key roles in determining the efficacy of insulin and phorbol ester signaling through the enzyme motifs (PMID:12032154)
• destruction of the surrounding matrix by endometriosis might be caused by various MMPs, which are mainly produced in stromal cells. (PMID:12034345)
• Oxidized low-density and high-density lipoproteins regulate the production by activated monocytes (PMID:12050187)
• lack of expression in Ewing sarcoma may be due to loss of accessibility of regulatory element to the specific fusion protein in vivo (PMID:12054564)
• Activation of p38 alpha MAPK enhances its expression by mRNA stabilization (PMID:12060661)
• Activation of protein kinase CK2 is an early step in the ultraviolet B-mediated increase in interstitial collagenase (matrix metalloproteinase-1; MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. (PMID:12071839)
• Results demonstrate that generation of the 44-kDa membrane type-1 matrix metalloproteinase (MT1-MMP) autolysis product regulates collagenolytic activity and subsequent invasive potential. (PMID:12145314)
• keratinocyte-fibroblast interactions are mediated by multiple stimulating agents acting on specific receptors to induce signalling through different mitogen-activated protein kinase pathways leading to altered expression of key biological functions. (PMID:12177784)
• Association of a polymorphism of the matrix metalloproteinase-1 gene with bone mineral density.Bone density for the distal radius was significantly lower in postmenopausal women with the GG/GG genotype. (PMID:12225803)
• MMP1 may play a pivotal role in the formation of capillarylike tubular structures in a collagen-containing fibrin matrix in vitro and may be involved in angiogenesis in a fibrinous exudate in vivo. (PMID:12393408)
• Genotyping was carried out using PCR-RFLP and direct sequencing. In the MMP-1 gene polymorphism, the frequency of the 2G/2G genotype that is associated with higher enzyme activity was significantly increased in colorectal cancer patients (PMID:12432557)
• viral LMP1 and Zta proteins regulate the expression and activity of MMP-1; first evidence that viral proteins are capable of regulating MMP-1 and clues for the role of EBV in nasopharyngeal carcinoma progression (PMID:12517806)
• A novel promoter element was detected in the human MMP1 gene, and the inflammation-responsive transcription factor SAF-1 was found to interact with it in osteoarthritis (PMID:12528113)
• a polymorphism in the promoter region is associated with the severe chronic periodontitis phenotype in non-smokers (PMID:12622858)
• expression and regulation by intestinal myofibroblasts in inflammatory bowel disease (PMID:12651627)
• catalytic activity on the cell surface is regulated through a vacuolar H(+)-ATPase-dependent degradation process (PMID:12667140)
• MMP-1 induces progressive adult-onset emphysema by the selective degradation of type III collagen within the alveolar wall. (PMID:12676763)
• Gene expression for MMP-1 after UVA1 irradiation was induced in all fibroblasts, but the induction rate was greater in systemic sclerosis fibroblasts than in normal ones. (PMID:12692352)
• MMP1 has a role in tumor invasion [review] (PMID:12706853)
• MT1-MMP-catalyzed release of beta-amyloid precursor protein leads to reduction of the extracellular matrix-associated gelatinase A inhibitor, sAPP, thus making it feasible for gelatinase A to exert proteolytic activity only near its activator, MT1-MMP (PMID:12767235)
• MMP-1 epitope increased interleukin 4 (IL-4) production of rheumatoid arthritis lymphocytes and decreased IL-4 production by control lymphocytes (PMID:12784383)
• These data provide evidence that tissue factor pathway inhibitor-2 does not bind to matrix metalloproteinases-2, -9 or -1, or regulate matrix metalloproteinase-1, in the extracellular matrix. (PMID:12787920)
• Hypoxia may be responsible for delayed wound healing by inducing an increase of MMP-1 synthesis. (PMID:12788533)
• MMP1 is a senescence-associated gene in normal human oral keratinocytes. (PMID:12837283)
• A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with renal cell carcinoma (PMID:12845675)
• study showed no change in metalloproteinase-1 production in response to varying estrogen levels in fibroblasts that were derived from incontinent women (PMID:12861139)
• Patients with deteriorating heart failure have increased expression of TIMP1 and MMP1 mRNA. Correlation with pro-inflammatory cytokines suggests common pathways of regulation and potential activation by IL-6 and IL1-beta. (PMID:12873541)
• Upregulation of mmp-1 ia assiciated with neoplasm invasiveness in Hereditary nonpolyposis colorectal cancers (PMID:12949792)
• monocyte matrix metalloproteinase-1 and -9 are differentially regulated by interferon gamma through tumor necrosis factor-alpha and caspase 8 (PMID:12960156)
• reported association between the matrix metalloproteinase 1 promoter polymorphism and ovarian cancer risk was not supported by our (PMID:12969782)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	mmp13a.2	ENSDARG00000012395
danio_rerio		ENSDARG00000108401
danio_rerio	mmp13a.1	ENSDARG00000114451
mus_musculus	Mmp1b	ENSMUSG00000041620
mus_musculus	Mmp1a	ENSMUSG00000043089
rattus_norvegicus	Mmp1b	ENSRNOG00000008881
rattus_norvegicus	Mmp1	ENSRNOG00000032353
caenorhabditis_elegans		WBGENE00010524
caenorhabditis_elegans		WBGENE00012185
caenorhabditis_elegans		WBGENE00012364
caenorhabditis_elegans		WBGENE00016283
caenorhabditis_elegans		WBGENE00194737

Paralogs (23): MMP25 (ENSG00000008516), MMP2 (ENSG00000087245), MMP11 (ENSG00000099953), MMP9 (ENSG00000100985), MMP15 (ENSG00000102996), HPX (ENSG00000110169), MMP8 (ENSG00000118113), MMP19 (ENSG00000123342), MMP24 (ENSG00000125966), MMP7 (ENSG00000137673), MMP20 (ENSG00000137674), MMP27 (ENSG00000137675), MMP13 (ENSG00000137745), MMP3 (ENSG00000149968), MMP21 (ENSG00000154485), MMP16 (ENSG00000156103), MMP14 (ENSG00000157227), MMP10 (ENSG00000166670), MMP26 (ENSG00000167346), MMP23B (ENSG00000189409), MMP17 (ENSG00000198598), MMP12 (ENSG00000262406), MMP28 (ENSG00000271447)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1933847) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 9 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased inflammatory response	1
decreased tumor growth/size	1
abnormal tumor morphology	1
decreased incidence of tumors by chemical induction	1
increased interferon-gamma secretion	1
abnormal interleukin secretion	1
increased interleukin-1 alpha secretion	1
increased interleukin-17 secretion	1
increased interleukin-2 secretion	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RES1	98.8%	Diamond
Sus scrofa	Q9XT90	96.7%	Diamond
Bos taurus	Q9GLE4	95.2%	Diamond
Oryctolagus cuniculus	Q95220	91.1%	Diamond
Equus caballus	O18927	90.5%	Diamond
Tupaia belangeri	Q9GKE1	85.2%	Diamond
Gallus gallus	Q90611	85.0%	Diamond
Canis lupus familiaris	Q6Y4Q5	78.9%	Diamond
Aquarana catesbeiana	Q11133	75.3%	Diamond
Felis catus	P55032	72.5%	Diamond
Arabidopsis thaliana	Q5XF51	71.1%	Diamond
Paracentrotus lividus	P22757	70.4%	Diamond
Hemicentrotus pulcherrimus	P91953	70.4%	Diamond
Xenopus laevis	Q10835	69.4%	Diamond
Glycine max	P29136	48.7%	Diamond
Tannerella forsythia 92A2	D0EM77	45.2%	Diamond
Drosophila melanogaster	Q8MPP3	44.0%	Diamond
Heliothis virescens ascovirus 3e	A4KX75	59.2%	Diamond
Spodoptera frugiperda ascovirus 1a	Q0E587	59.2%	Diamond
Invertebrate iridescent virus 6	O55761	46.9%	Diamond
Invertebrate iridescent virus 3	Q196W5	43.3%	Diamond
Trichoplusia ni ascovirus 2c	Q06VC5	41.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MMP3	protein-coding	4314
MMP10	protein-coding	4319
MMP12	protein-coding	4321
MMP8	protein-coding	4317
MMP27	protein-coding	64066

Protein

Protein identifiers

Interstitial collagenase — P03956 (reviewed: P03956)

Alternative names: Fibroblast collagenase, Matrix metalloproteinase-1

All UniProt accessions (1): P03956

UniProt curated annotations — full annotation on UniProt →

Function. Cleaves collagens of types I, II, and III at one site in the helical domain. Also cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat’s mediated neurotoxicity.

Subunit / interactions. (Microbial infection) Interacts with HIV-1 Tat.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Post-translational modifications. Undergoes autolytic cleavage to two major forms (22 kDa and 27 kDa). A minor form (25 kDa) is the glycosylated form of the 22 kDa form. The 27 kDa form has no activity while the 22/25 kDa form can act as activator for collagenase. Tyrosine phosphorylated in platelets by PKDCC/VLK.

Activity regulation. Can be activated without removal of the activation peptide.

Cofactor. Binds 4 Ca(2+) ions per subunit. Binds 2 Zn(2+) ions per subunit.

Domain organisation. There are two distinct domains in this protein; the catalytic N-terminal, and the C-terminal which is involved in substrate specificity and in binding TIMP (tissue inhibitor of metalloproteinases). The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.

Similarity. Belongs to the peptidase M10A family.

RefSeq proteins (2): NP_001139410, NP_002412* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000585	Hemopexin-like_dom	Domain
IPR001818	Pept_M10_metallopeptidase	Domain
IPR002477	Peptidoglycan-bd-like	Domain
IPR006026	Peptidase_Metallo	Domain
IPR018486	Hemopexin_CS	Conserved_site
IPR018487	Hemopexin-like_repeat	Repeat
IPR021158	Pept_M10A_Zn_BS	Binding_site
IPR021190	Pept_M10A	Family
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR033739	M10A_MMP	Domain
IPR036365	PGBD-like_sf	Homologous_superfamily
IPR036375	Hemopexin-like_dom_sf	Homologous_superfamily

Pfam: PF00045, PF00413, PF01471

Enzyme classification (BRENDA)

• EC 3.4.24.7 — interstitial collagenase (BRENDA: 11 organisms, 121 substrates, 166 inhibitors, 52 Km, 47 kcat entries)

Substrate kinetics (BRENDA)

28 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
COLLAGEN I ALPHA-1 CHAIN	0.0009–0.74	8
COLLAGEN I ALPHA-2 CHAIN	0.0003–0.53	8
HUMAN TYPE I COLLAGEN	0.0005–0.0011	4
HUMAN TYPE III COLLAGEN	0.0013–0.0024	3
ALPHA1(I)772-786 TRIPLE-HELICAL PEPTIDE	0.063–0.2076	2
FTHP-3	0.0612–0.0666	2
HUMAN TYPE II COLLAGEN	0.001–0.0021	2
2,4-DINITROPHENYL-PRO-BETA-CYCLOHEXYL-ALA-GLY-CY	0.013	1
2,4-DINITROPHENYL-PRO-LEU-ALA-LEU-TRP-ALA-ARG-OH	0.026	1
ACETYL-PRO-LEU-GLY-ILE-LEU-GLY-OC2H5	0.0013	1
ACETYL-PRO-LEU-GLY-LEU-LEU-GLY-OC2H5	0.0012	1
ACETYL-PRO-LEU-GLY-SCH[CH2CH(CH3)2CO]-LEU-LEU-OC	0.0039	1
BOVINE TYPE I COLLAGEN	0.0002	1
GLY-PRO-GLN-GLY-ILE-ALA-GLY-GLN-GLN	3.3	1
GLY-PRO-GLN-GLY-ILE-ALA-GLY-GLN-GLN-ARG-GLY-VAL-	0.63	1

UniProt features (106 total): strand 31, binding site 24, helix 13, sequence conflict 7, sequence variant 6, turn 5, repeat 4, chain 3, modified residue 3, site 2, signal peptide 1, propeptide 1, short sequence motif 1, active site 1, glycosylation site 1, disulfide bond 1, mutagenesis site 1, region of interest 1

Structure

Experimental structures (PDB)

15 structures by resolution:

PDB	Title	Method	Resolution (Å)
1HFC	1.56 ANGSTROM STRUCTURE OF MATURE TRUNCATED HUMAN FIBROBLAST COLLAGENASE	X-RAY DIFFRACTION	1.5
1CGE	CRYSTAL STRUCTURES OF RECOMBINANT 19-KDA HUMAN FIBROBLAST COLLAGENASE COMPLEXED TO ITSELF	X-RAY DIFFRACTION	1.9
966C	CRYSTAL STRUCTURE OF FIBROBLAST COLLAGENASE-1 COMPLEXED TO A DIPHENYL-ETHER SULPHONE …	X-RAY DIFFRACTION	1.9
1CGF	CRYSTAL STRUCTURES OF RECOMBINANT 19-KDA HUMAN FIBROBLAST COLLAGENASE COMPLEXED TO ITSELF	X-RAY DIFFRACTION	2.1
1SU3	X-ray structure of human proMMP-1: New insights into collagenase action	X-RAY DIFFRACTION	2.2
2TCL	STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH AN …	X-RAY DIFFRACTION	2.2
3SHI	Crystal structure of human MMP1 catalytic domain at 2.2 A resolution	X-RAY DIFFRACTION	2.2
1CGL	Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor	X-RAY DIFFRACTION	2.4
2J0T	Crystal Structure of the Catalytic Domain of MMP-1 in Complex with the Inhibitory Domain …	X-RAY DIFFRACTION	2.54
2CLT	Crystal structure of the active form (full-length) of human fibroblast collagenase.	X-RAY DIFFRACTION	2.67
4AUO	Crystal structure of MMP-1(E200A) in complex with a triple-helical collagen peptide	X-RAY DIFFRACTION	3
1AYK	INHIBITOR-FREE CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE, NMR, 30 STRUCTURES	SOLUTION NMR
2AYK	INHIBITOR-FREE CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE, NMR, MINIMIZED AVERAGE …	SOLUTION NMR
3AYK	CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH CGS-27023A, NMR …	SOLUTION NMR
4AYK	CATALYTIC FRAGMENT OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH CGS-27023A, NMR, 30 …	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P03956-F1	91.29	0.85

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Peptidases, Metallopeptidases, Predicted secreted proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers, Candidate cardiovascular disease genes, Human disease related genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles

Antibody reliability (HPA): IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3)

Position	Role
219
143	not glycosylated
269–270	cleavage; by autolysis

Ligand- & substrate-binding residues (24)

Position	Role
92	Zn(2+)
124	Ca(2+)
158	Ca(2+)
168	Zn(2+)
170	Zn(2+)
175	Ca(2+)
176	Ca(2+)
178	Ca(2+)
180	Ca(2+)
183	Zn(2+)
190	Ca(2+)
192	Ca(2+)
194	Ca(2+)
196	Zn(2+)
198	Ca(2+)
199	Ca(2+)
201	Ca(2+)
218	Zn(2+)
222	Zn(2+)
228	Zn(2+)
285	Ca(2+)
329	Ca(2+)
378	Ca(2+)
427	Ca(2+)

Post-translational modifications (3)

Type	Positions
Phosphoserine	57
Phosphothreonine	274
Phosphotyrosine	360

Disulfide bonds (1)

Type	Positions
Disulfide bond	278–466

Glycosylation sites (1)

Type	Positions
N-linked (glcnac…) asparagine	120

Mutagenesis-validated functional residues (1)

Position	Phenotype
360	partial reduction of tyrosine phosphorylation in the presence of pkdcc/vlk.

Function

Pathways and Gene Ontology

Reactome pathways

4 curated (TAS) of 13; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

13 pathways:

ID	Pathway	Evidence
R-HSA-1592389	Activation of Matrix Metalloproteinases	curated
R-HSA-210991	Basigin interactions	curated
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	curated
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	curated
R-HSA-202733	Cell surface interactions at the vascular wall	—
R-HSA-1442490	Collagen degradation	electronic
R-HSA-1280215	Cytokine Signaling in Immune system	—
R-HSA-1474228	Degradation of the extracellular matrix	electronic
R-HSA-1474244	Extracellular matrix organization	—
R-HSA-109582	Hemostasis	—
R-HSA-168256	Immune System	—
R-HSA-392499	Metabolism of proteins	—
R-HSA-449147	Signaling by Interleukins	—

MSigDB gene sets: 448 (showing top): MODULE_172, AHRARNT_01, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, MODULE_52, MCLACHLAN_DENTAL_CARIES_UP, YAGI_AML_WITH_INV_16_TRANSLOCATION, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_CELLULAR_RESPONSE_TO_UV, chr11q22, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, MODULE_128, SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER, GNF2_PTX3, PID_REG_GR_PATHWAY

GO Biological Process (6): proteolysis (GO:0006508), extracellular matrix disassembly (GO:0022617), extracellular matrix organization (GO:0030198), collagen catabolic process (GO:0030574), positive regulation of protein-containing complex assembly (GO:0031334), cellular response to UV-A (GO:0071492)

GO Molecular Function (8): endopeptidase activity (GO:0004175), metalloendopeptidase activity (GO:0004222), serine-type endopeptidase activity (GO:0004252), peptidase activity (GO:0008233), zinc ion binding (GO:0008270), metallopeptidase activity (GO:0008237), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (2): extracellular region (GO:0005576), extracellular matrix (GO:0031012)

Reactome top-level categories

8 top-level categories:

Category	Pathways
Degradation of the extracellular matrix	2
Extracellular matrix organization	1
Cell surface interactions at the vascular wall	1
Metabolism of proteins	1
Signaling by Interleukins	1
Immune System	1
Hemostasis	1
Cytokine Signaling in Immune system	1

GO top-level categories

24 GO namespaces:

Category	Terms
peptidase activity	2
endopeptidase activity	2
protein metabolic process	1
cellular component disassembly	1
extracellular matrix organization	1
extracellular structure organization	1
external encapsulating structure organization	1
catabolic process	1
collagen metabolic process	1
regulation of protein-containing complex assembly	1
positive regulation of cellular component biogenesis	1
positive regulation of cellular component organization	1
protein-containing complex assembly	1
cellular response to UV	1
response to UV-A	1
metallopeptidase activity	1
serine-type peptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
transition metal ion binding	1
catalytic activity	1
cation binding	1
cellular anatomical structure	1
external encapsulating structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 16 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
cellular response to UV-A	BP	direct assay
positive regulation of protein-containing complex assembly	BP	direct assay
proteolysis	BP	direct assay
endopeptidase activity	MF	direct assay
metalloendopeptidase activity	MF	direct assay
peptidase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 2,770 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MMP1	TIMP1	P01033	929
MMP1	TIMP2	P16035	854
MMP1	IL1B	P01584	816
MMP1	ELN	P15502	810
MMP1	FN1	P02751	797
MMP1	PITRM1	Q5JRX3	794
MMP1	ADAMTS3	O15072	752
MMP1	TNF	P01375	749
MMP1	IL6	P05231	741
MMP1	ADAMTS4	O75173	733
MMP1	TIMP4	Q99727	730
MMP1	PTGS2	P35354	730
MMP1	F2R	P25116	729
MMP1	CXCL8	P10145	720
MMP1	TGFB1	P01137	719

IntAct

Human interaction partners of MMP1 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

2 partners by confidence:

Partner	Interaction type	MIscore	Records
SOX8	physical association	0.370	1
F2R	proximity	0.270	1

BioGRID (28 interactions; top human partners by supporting records): ITGA2 (Reconstituted Complex; 2 records), BCAN (Biochemical Activity), BSG (Affinity Capture-Western), CSK (Synthetic Lethality), CSNK2A1 (Affinity Capture-MS), CSNK2A2 (Affinity Capture-MS), CSNK2A3 (Affinity Capture-MS), DCLK1 (Co-localization), F2R (Co-localization), GNAI1 (Affinity Capture-Western), MB21D1 (Affinity Capture-MS), MMP12 (Negative Genetic), MMP16 (Negative Genetic), MMP17 (Negative Genetic), MMP2 (Negative Genetic)

SIGNOR signaling

showing 13 of 14 signaling interactions:

A	Effect	B	Mechanism
FBN1	“up-regulates quantity by expression”	MMP1	“transcriptional regulation”
MMP1	up-regulates	Angiogenesis
CITED2	“down-regulates quantity by repression”	MMP1	“transcriptional regulation”
MMP1	“down-regulates quantity by destabilization”	COL2A1	cleavage
ZMYND8	“down-regulates quantity by repression”	MMP1	“transcriptional regulation”
MMP1	“up-regulates activity”	HBEGF	cleavage
WNT7A	“up-regulates quantity by expression”	MMP1	“transcriptional regulation”
ZNF384	“up-regulates quantity by expression”	MMP1	“transcriptional regulation”
MMP1	“down-regulates quantity by destabilization”	COL1A1	cleavage
MMP1	“down-regulates quantity by destabilization”	COL1A2	cleavage
MMP1	“down-regulates quantity by destabilization”	COL3A1	cleavage
MMP1	up-regulates	ECM_disassembly
MMP1	down-regulates	ECM

Disease & clinical

Genetic variants

Variant evidence for MMP1: 149 ClinVar records (0 pathogenic / likely pathogenic); 1 CIViC cancer variant; 2 GWAS associations.

ClinVar

149 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	81
Likely benign	20
Benign	38

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 39 predictions of 341):

Position(s)	Effect	Δscore	Sites
11:102790701–102790702	donor_loss	1.0000	5
11:102790807–102790808	acceptor_loss	1.0000	5
11:102791331–102791332	donor_loss	1.0000	5
11:102792603–102792604	donor_loss	1.0000	4
11:102792677	acceptor_gain	1.0000
11:102795172–102795173	donor_loss	1.0000	4
11:102795292–102795293	acceptor_loss	1.0000	4
11:102795450–102795451	donor_loss	1.0000	5
11:102796663	donor_loss	1.0000	2
11:102796790–102796791	acceptor_loss	1.0000	4

AlphaMissense

903 missense substitutions predicted likely pathogenic (of 3,141 scored), across 235 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M236	9	0.924	0.991
H222	8	0.980	0.993
D252	8	0.978	0.992
F174	8	0.976	0.997
H218	8	0.976	0.992
H228	8	0.972	0.993
H183	8	0.971	0.989
D170	8	0.970	0.986
F163	8	0.966	0.996
H168	8	0.955	0.985
H196	8	0.953	0.985
D198	8	0.948	0.974
D96	8	0.913	0.963
F197	8	0.911	0.989
D194	8	0.887	0.944
F149	8	0.864	0.979
F392	8	0.833	0.936
D175	8	0.783	0.888
F185	7	0.982	0.997
C92	7	0.981	0.991

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Head and Neck Squamous Cell Carcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	3.71e-07
Kidney Chromophobe (TCGA)	unfavorable	2.45e-05
Kidney Renal Papillary Cell Carcinoma (TCGA)	unfavorable	2.86e-05
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	unfavorable	8.52e-05

Disease associations

OMIM: gene MIM:120353 | disease phenotypes:

HPO phenotypes

58 phenotypes (HPO-id order):

HPO	Term
HP:0000079	Abnormality of the urinary system
HP:0000083	Renal insufficiency
HP:0000099	Glomerulonephritis
HP:0000160	Narrow mouth
HP:0000478	Abnormality of the eye
HP:0000572	Visual loss
HP:0000670	Carious teeth
HP:0000716	Depression
HP:0000739	Anxiety
HP:0000794	IgA deposition in the glomerulus
HP:0000823	Delayed puberty
HP:0000938	Osteopenia
HP:0000939	Osteoporosis
HP:0000982	Palmoplantar keratoderma
HP:0001030	Fragile skin
HP:0001056	Milia
HP:0001057	Aplasia cutis congenita
HP:0001075	Atrophic scars
HP:0001371	Flexion contracture
HP:0001510	Growth delay
HP:0001581	Recurrent skin infections
HP:0001644	Dilated cardiomyopathy
HP:0001798	Anonychia
HP:0001891	Iron deficiency anemia
HP:0001903	Anemia
HP:0001917	Renal amyloidosis
HP:0001965	Abnormal scalp morphology
HP:0002015	Dysphagia
HP:0002020	Gastroesophageal reflux
HP:0002671	Basal cell carcinoma
HP:0002839	Urinary bladder sphincter dysfunction
HP:0002860	Squamous cell carcinoma
HP:0004057	Mitten deformity
HP:0004386	Gastrointestinal inflammation
HP:0004395	Malnutrition
HP:0004791	Esophageal ulceration
HP:0006297	Enamel hypoplasia
HP:0008066	Abnormal blistering of the skin
HP:0008366	Foot joint contracture
HP:0008404	Nail dystrophy
HP:0010296	Ankyloglossia
HP:0011354	Generalized abnormality of skin
HP:0011936	Decreased plasma total carnitine
HP:0012056	Cutaneous melanoma
HP:0012227	Urethral stricture
HP:0012252	Abnormal respiratory system morphology
HP:0012390	Anal fissure
HP:0012532	Chronic pain
HP:0012622	Chronic kidney disease
HP:0031446	Erosion of oral mucosa
HP:0031464	Genital blistering
HP:0031831	Decreased serum zinc
HP:0031903	Abnormal circulating selenium concentration
HP:0032676	Chronic cutaneous wound
HP:0100508	Abnormality of vitamin metabolism
HP:0100512	Decreased circulating vitamin D concentration
HP:0200020	Corneal erosion
HP:0200097	Oral mucosal blisters

GWAS associations

2 associations:

Study	Trait	p-value
GCST006585_741	Blood protein levels	7e-107
GCST009731_28	Blood protein levels in cardiovascular risk	2e-82

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0008193	interstitial collagenase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2095216 (PROTEIN FAMILY), CHEMBL2111422 (SELECTIVITY GROUP), CHEMBL332 (SINGLE PROTEIN), CHEMBL4523984 (SELECTIVITY GROUP)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the MMP1 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

3 curated-mechanism drugs:

Drug	Modality	Max phase
DOXYCYCLINE	Small molecule	4
MARIMASTAT	Small molecule	3
REBIMASTAT	Small molecule	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 534,709 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

21 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL707	DOXAZOSIN	4	25,111
CHEMBL481	IRINOTECAN	4	161,851
CHEMBL56367	NIMESULIDE	4	25,616
CHEMBL2	PRAZOSIN	4	31,292
CHEMBL421	SULFASALAZINE	4	74,280
CHEMBL1200448	TILUDRONATE DISODIUM	4	5,540
CHEMBL279785	MARIMASTAT	3	29,705
CHEMBL145	CAFFEIC ACID	3	36,727
CHEMBL297453	EPIGALOCATECHIN GALLATE	3	23,201
CHEMBL75094	PRINOMASTAT	3	8,942
CHEMBL50	QUERCETIN	3	75,572
CHEMBL76222	REBIMASTAT	2	363
CHEMBL368347	(+)-SECOISOLARICIRESINOL	2	91
CHEMBL87223	AMINOQUINURIDE	2	1,385
CHEMBL206815	APRATASTAT	2	271
CHEMBL279786	BATIMASTAT	2	21,436
CHEMBL115653	CIPEMASTAT	2	380
CHEMBL440498	CTS-1027	2	651
CHEMBL19611	ILOMASTAT	2	12,186
CHEMBL2107228	SOLIMASTAT	2	109
CHEMBL261932	TANOMASTAT	2

Clinical evidence (CIViC)

Drug × variant × indication, from 1 curated evidence items. CIViC evidence level: A (validated) → B (clinical) → C (case study) → D (preclinical) → E (inferential).

1 predictive associations by evidence level:

Variant	Therapy	Indication	Effect	Level	CIViC
MMP1 Overexpression	Sacituzumab Govitecan	Estrogen Receptor-positive Breast Cancer	Resistance	CIViC D	EID12597

CIViC curated variants (1)

Named clinical variants curated in CIViC for this gene (the catalogue beneath the predictive evidence above):

Overexpression.

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

2 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs7945189	Antiinflammatory agents, non-steroids	Toxicity	Genotypes CT + TT are associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype CC.	PMID:20538124
rs2071230	Antiinflammatory agents, non-steroids	Toxicity	Genotypes AG + GG are associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype AA.	PMID:20538124

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M10: Matrix metallopeptidase

Most potent curated ligand interactions (6 total), top 6:

Ligand	Action	Affinity	Parameter
ilomastat	Inhibition	9.25	pIC50
batimastat	Inhibition	9.0	pIC50
cipemastat	Inhibition	8.5	pKi
marimastat	Inhibition	8.3	pIC50
apratastat	Inhibition	7.48	pIC50
CGS-27023A	Inhibition	7.25	pIC50

Binding affinities (BindingDB)

3271 measured of 3844 human assays (3860 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
(2R)-2-{[4-(4-bromophenyl)benzene]sulfonamido}-3-methylbutanoic acid	IC50	0.004 nM
N*1*-(2-Cyclohexyl-1-{2-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethylcarbamoyl}-ethyl)-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.01 nM
3-(3-{2-[5-(4-Chloro-phenyl)-2-hydroxycarbamoylmethyl-pentanoylamino]-3-cyclohexyl-propionylamino}-propionylamino)-propionic acid methyl ester	KI	0.01 nM
2-[3-(4-Chloro-phenyl)-propyl]-N*1*-(2-cyclohexyl-1-{2-[2-(morpholine-4-sulfonylamino)-ethylcarbamoyl]-ethylcarbamoyl}-ethyl)-N*4*-hydroxy-succinamide	KI	0.01 nM
N*1*-(2-Cyclohexyl-1-{2-[2-(morpholine-4-sulfonylamino)-ethylcarbamoyl]-ethylcarbamoyl}-ethyl)-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.01 nM
N*1*-{2-Cyclohexyl-1-[2-(2-morpholin-4-yl-ethylcarbamoyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.01 nM
3-(3-{2-[5-(4-Chloro-phenyl)-2-hydroxycarbamoylmethyl-pentanoylamino]-3-cyclohexyl-propionylamino}-propionylamino)-propionic acid	KI	0.01 nM
3-{(S)-2-[(R)-5-(4-Chloro-phenyl)-2-hydroxycarbamoylmethyl-pentanoylamino]-3-cyclohexyl-propionylamino}-propionic acid	KI	0.01 nM
(R)-N*1*-{(S)-2-Cyclohexyl-1-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.01 nM
(R)-N*1*-[(S)-2-Cyclohexyl-1-(2-morpholin-4-yl-ethylcarbamoyl)-ethyl]-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.01 nM
(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-{(S)-2-cyclohexyl-1-[2-(morpholine-4-sulfonylamino)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-succinamide	KI	0.01 nM
3-{(S)-2-[(R)-5-(4-Chloro-phenyl)-2-hydroxycarbamoylmethyl-pentanoylamino]-3-cyclohexyl-propionylamino}-propionic acid methyl ester	KI	0.01 nM
(R)-N*1*-{(S)-2-Cyclohexyl-1-[2-(morpholine-4-sulfonylamino)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.01 nM
N*1*-{2-Cyclohexyl-1-[2-(4-dimethylamino-butylcarbamoyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.02 nM
2-[3-(4-Chloro-phenyl)-propyl]-N*1*-{2-cyclohexyl-1-[2-(3-morpholin-4-yl-3-oxo-propylcarbamoyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-succinamide	KI	0.02 nM
N*1*-{2-Cyclohexyl-1-[2-(4-morpholin-4-yl-butylcarbamoyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.02 nM
(R)-N*1*-[(S)-2-Cyclohexyl-1-(4-morpholin-4-yl-butylcarbamoyl)-ethyl]-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.02 nM
(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-[(S)-2-cyclohexyl-1-(3-morpholin-4-yl-3-oxo-propylcarbamoyl)-ethyl]-N*4*-hydroxy-succinamide	KI	0.02 nM
(R)-N*1*-[(S)-2-Cyclohexyl-1-(4-dimethylamino-butylcarbamoyl)-ethyl]-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.02 nM
alpha-tetrahydropyran beta-sulfone 1B	IC50	0.029 nM
(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-((S)-2-cyclohexyl-1-phenethylcarbamoyl-ethyl)-N*4*-hydroxy-succinamide	KI	0.03 nM
2-[3-(4-Chloro-phenyl)-propyl]-N*1*-{2-cyclohexyl-1-[2-(4-morpholin-4-yl-butylcarbamoyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-succinamide	KI	0.03 nM
2-[3-(4-Chloro-phenyl)-propyl]-N*1*-(2-cyclohexyl-1-{2-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethylcarbamoyl}-ethyl)-N*4*-hydroxy-succinamide	KI	0.03 nM
(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-{(S)-2-cyclohexyl-1-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-succinamide	KI	0.03 nM
(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-[(S)-2-cyclohexyl-1-(4-morpholin-4-yl-butylcarbamoyl)-ethyl]-N*4*-hydroxy-succinamide	KI	0.03 nM
CHEMBL5412341	IC50	0.034 nM
N-Hydroxy-2-(4-phenoxy-benzenesulfonylamino)-acetamide	IC50	0.04 nM
AG-3340	IC50	0.048 nM
(S)-2,2-Dimethyl-4-[4-(pyridin-3-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid hydroxyamide	IC50	0.048 nM
2-[3-(4-Chloro-phenyl)-propyl]-N*1*-{2-cyclohexyl-1-[2-(4-dimethylamino-butylcarbamoyl)-ethylcarbamoyl]-ethyl}-N*4*-hydroxy-succinamide	KI	0.05 nM
(R)-2-[3-(4-Chloro-phenyl)-propyl]-N*1*-[(S)-2-cyclohexyl-1-(4-dimethylamino-butylcarbamoyl)-ethyl]-N*4*-hydroxy-succinamide	KI	0.05 nM
CHEMBL473539	IC50	0.05 nM
CHEMBL5182207	IC50	0.055 nM
(R)-N*1*-((S)-2-Cyclohexyl-1-phenethylcarbamoyl-ethyl)-N*4*-hydroxy-2-(3-phenyl-propyl)-succinamide	KI	0.06 nM
(R)-N*1*-((S)-2-Cyclohexyl-1-phenethylcarbamoyl-ethyl)-2-[3-(4-fluoro-phenyl)-propyl]-N*4*-hydroxy-succinamide	KI	0.06 nM
N*1*-(2-Cyclohexyl-1-phenethylcarbamoyl-ethyl)-N*4*-hydroxy-2-[3-(4-methoxy-phenyl)-propyl]-succinamide	KI	0.06 nM
2-(4’-Chloro-biphenyl-4-ylsulfanylmethyl)-N-hydroxy-4-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-butyramide	IC50	0.06 nM
CHEMBL5185612	IC50	0.068 nM
6-Hydroxy-2-(4-nitro-benzenesulfonyl)-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid hydroxyamide	IC50	0.076 nM
(R)-N*1*-((S)-2-Cyclohexyl-1-phenethylcarbamoyl-ethyl)-N*4*-hydroxy-2-(3-p-tolyl-propyl)-succinamide	KI	0.08 nM
(R)-2-[(Biphenyl-4-sulfonyl)-isopropoxy-amino]-N-hydroxy-3-methyl-butyramide	IC50	0.09 nM
2-(Formyl-hydroxy-amino)-3-[4-(4-trifluoromethoxy-phenoxy)-benzenesulfonyl]-propane-1-sulfonic acid dimethylamide	IC50	0.098 nM
N-hydroxy-1-(2-methoxyethyl)-4-[(4-phenoxybenzene)sulfonyl]piperidine-4-carboxamide hydrochloride	KI	0.1 nM
1-Cyclopropyl-N-hydroxy-4-{[4-(phenylthio)phenyl]-sulfonyl}piperidine-4-carboxamide Hydrochloride	KI	0.1 nM
N-hydroxy-2-methyl-2-[(4-phenoxybenzene)sulfonyl]propanamide	KI	0.1 nM
(7S,8R,11S)-9-Oxo-8-[2-(4-propyl-phenyl)-ethyl]-2-oxa-10-aza-bicyclo[11.2.2]heptadeca-1(16),13(17),14-triene-7,11-dicarboxylic acid 7-hydroxyamide 11-methylamide	IC50	0.1 nM
(R)-4-[(Z)-Benzyloxyimino]-1-(4-butoxy-benzenesulfonyl)-pyrrolidine-2-carboxylic acid hydroxyamide	IC50	0.1 nM
2-(4’-Chloro-biphenyl-4-yloxymethyl)-N-hydroxy-4-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-butyramide	IC50	0.1 nM
(R)-N*1*-((S)-2-Cyclohexyl-1-phenethylcarbamoyl-ethyl)-2-[3-(4-ethyl-phenyl)-propyl]-N*4*-hydroxy-succinamide	KI	0.1 nM
(2R,3S)-N1-((S)-3-(4-guanidinophenyl)-1-(methylamino)-1-oxopropan-2-yl)-N4-hydroxy-2-isobutyl-3-(3-phenylpropyl)succinamide	IC50	0.1 nM

ChEMBL bioactivities

2751 potent at pChembl≥5 of 3190 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.00	Ki	0.1	nM	CHEMBL281795
10.00	EC50	0.1	nM	CHEMBL526566
9.70	IC50	0.2	nM	ILOMASTAT
9.59	IC50	0.26	nM	CHEMBL321180
9.52	Ki	0.3	nM	CIPEMASTAT
9.52	IC50	0.3	nM	CHEMBL279078
9.40	IC50	0.4	nM	CHEMBL4088630
9.40	Ki	0.4	nM	ILOMASTAT
9.40	IC50	0.4	nM	ILOMASTAT
9.40	IC50	0.4	nM	BATIMASTAT
9.40	IC50	0.4	nM	CHEMBL141080
9.30	Ki	0.5	nM	BATIMASTAT
9.30	IC50	0.5	nM	ILOMASTAT
9.30	IC50	0.5	nM	CHEMBL74670
9.30	IC50	0.5	nM	CHEMBL139886
9.25	IC50	0.56	nM	ILOMASTAT
9.22	Ki	0.6	nM	CHEMBL353382
9.22	Ki	0.6	nM	CHEMBL433314
9.15	Ki	0.7	nM	CHEMBL382705
9.15	Ki	0.7	nM	CHEMBL208181
9.15	Ki	0.7	nM	MARIMASTAT
9.15	IC50	0.7	nM	CHEMBL140511
9.12	IC50	0.75	nM	BATIMASTAT
9.11	IC50	0.78	nM	MARIMASTAT
9.10	IC50	0.8	nM	CHEMBL140970
9.10	EC50	0.8	nM	CHEMBL526106
9.06	IC50	0.88	nM	CHEMBL144611
9.06	Ki	0.87	nM	CHEMBL417537
9.01	Ki	0.97	nM	CHEMBL172885
9.00	Ki	1	nM	CHEMBL30980
9.00	IC50	0.99	nM	BATIMASTAT
9.00	IC50	1	nM	CHEMBL207776
9.00	Ki	1	nM	CHEMBL72511
9.00	Ki	1	nM	CHEMBL324947
9.00	Ki	1	nM	CHEMBL114458
9.00	Ki	1	nM	CHEMBL389020
9.00	IC50	1	nM	MARIMASTAT
9.00	IC50	1	nM	CHEMBL73763
9.00	IC50	1	nM	CHEMBL344633
9.00	IC50	1	nM	CHEMBL337594
8.96	IC50	1.1	nM	CHEMBL144843
8.96	IC50	1.1	nM	CHEMBL432991
8.96	IC50	1.1	nM	CHEMBL4785595
8.96	Ki	1.1	nM	CHEMBL72511
8.96	Ki	1.1	nM	MARIMASTAT
8.96	IC50	1.1	nM	MARIMASTAT
8.92	IC50	1.2	nM	CHEMBL344759
8.92	Ki	1.2	nM	CHEMBL45631
8.92	IC50	1.2	nM	CHEMBL6572
8.92	IC50	1.2	nM	BATIMASTAT

PubChem BioAssay actives

2567 with measured affinity, of 5224 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N,6-dihydroxy-2-(4-nitrophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-1-carboxamide	731524: Inhibition of MMP1 (unknown origin)	ic50	<0.0001	uM
[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] N-(2,2-dimethylpropyl)carbamate	362585: Inhibition of glucocorticoid-mediated human MMP1 expression in PMA stimulated A549 cells assessed as MMP1 protein level by ELISA	ec50	0.0001	uM
(2R)-N’-hydroxy-N-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide	628300: Inhibition of MMP1	ic50	0.0002	uM
(2S,3R)-N-hydroxy-2-methyl-N’-[(2S)-1-(methylamino)-1-oxo-3-(5,6,7,8-tetrahydronaphthalen-1-yl)propan-2-yl]-3-(2-methylpropyl)butanediamide	108731: Activity against Matrix metalloprotease-1 (MMP-1).	ic50	0.0003	uM
(2S,3R)-N,2-dihydroxy-N’-[(2S)-1-(1H-indol-3-yl)-3,3-dimethyl-1-oxobutan-2-yl]-3-(2-methylpropyl)butanediamide	104923: In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA	ic50	0.0003	uM
(2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-piperidin-1-yl-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide	264663: Binding affinity to recombinant MMP1	ki	0.0003	uM
(3S)-N-hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0004	uM
N-hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide	1454754: Inhibition of human interstitial recombinant N-terminal MMP1 expressed in Escherichia coli BL21(DE3) using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as substrate after 20 to 30 mins by spectrofluorimetric analysis	ic50	0.0004	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide	108731: Activity against Matrix metalloprotease-1 (MMP-1).	ic50	0.0004	uM
(3S)-4-(4-bromo-2-methylphenyl)sulfonyl-N-hydroxy-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0005	uM
(2R,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-3-(hydroxymethyl)-2-(2-methylpropyl)butanediamide	109221: Inhibitory potency against Matrix metalloprotease-1 (MMP-1)	ki	0.0006	uM
(2R,3R)-N,2-dihydroxy-N’-[(2S)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-methyl-3-(2-methylpropyl)butanediamide	104557: Binding affinity was evaluated against matrix metalloprotease-1	ki	0.0006	uM
(3S)-4-(4-bromophenyl)sulfonyl-N-hydroxy-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0007	uM
(2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-methylpiperidine-2-carboxamide	264663: Binding affinity to recombinant MMP1	ki	0.0007	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’,3-dihydroxy-2-(2-methylpropyl)butanediamide	109221: Inhibitory potency against Matrix metalloprotease-1 (MMP-1)	ki	0.0007	uM
(2S,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(4-methoxyphenyl)-3-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanediamide	264663: Binding affinity to recombinant MMP1	ki	0.0007	uM
[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] N-butan-2-ylcarbamate	362585: Inhibition of glucocorticoid-mediated human MMP1 expression in PMA stimulated A549 cells assessed as MMP1 protein level by ELISA	ec50	0.0008	uM
(3S)-N-hydroxy-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0008	uM
(2S,3R)-N-hydroxy-N’-[(2R)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-methyl-3-(2-methylpropyl)butanediamide	109228: Inhibition of MMP-1 (Matrix metalloprotease-1)	ki	0.0009	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-3-[(1-methyl-2-oxoquinolin-6-yl)methoxy]-2-(2-methylpropyl)butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0009	uM
(2R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-[4-(4-methoxyphenoxy)butyl]butanediamide	52368: Inhibitory potency against human fibroblast collagenase, MMP-1	ki	0.0010	uM
(2S,11S,12R)-11-N-hydroxy-2-N-methyl-7-(1-methylimidazol-4-yl)sulfonyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(3R)-6-cyclohexyl-N-hydroxy-3-[3-(methanesulfonamidomethyl)-1,2,4-oxadiazol-5-yl]hexanamide	349373: Inhibition of MMP1	ki	0.0010	uM
(6S)-N-hydroxy-7-(4-methoxyphenyl)sulfonyl-5,5-dimethyl-1,4,7-oxathiazonane-6-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0010	uM
(3S)-N-hydroxy-2,2-dimethyl-4-(5-pyridin-2-ylthiophen-2-yl)sulfonyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0010	uM
(8S,11R,12S)-12-N-hydroxy-8-N-methyl-11-(2-methylpropyl)-2,10-dioxo-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(2S,11S,12R)-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
tert-butyl (6S,9R,10S)-10-(hydroxycarbamoyl)-6-(methylcarbamoyl)-9-(2-methylpropyl)-8-oxo-1,7-diazacyclotridecane-1-carboxylate	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(7S,8R,11S)-7-N-hydroxy-11-N-methyl-8-(2-methylpropyl)-9-oxo-6-oxa-1,10-diazatricyclo[11.6.1.014,19]icosa-13(20),14,16,18-tetraene-7,11-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(4R,7R,8S)-8-N-hydroxy-4-N-methyl-7-(2-methylpropyl)-6,11-dioxo-9-oxa-2-thia-5,12-diazabicyclo[11.4.0]heptadeca-1(17),13,15-triene-4,8-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(2S,11S,12R)-7-(benzenesulfonyl)-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(9S,12R,13S)-13-N-hydroxy-9-N,4-dimethyl-12-(2-methylpropyl)-3,11-dioxo-1-oxa-4,10-diazacyclotridecane-9,13-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(8S,11R,12S)-12-N-hydroxy-8-N,3-dimethyl-11-(2-methylpropyl)-2,10-dioxo-1-oxa-3,9-diazacyclopentadecane-8,12-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0010	uM
(2R)-N’-hydroxy-N-[(2S)-3-(4-methoxyphenyl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide	108923: Inhibition of matrix metalloprotease-1	ki	0.0010	uM
(3S)-N-hydroxy-2,2-dimethyl-4-(4-prop-2-ynoxyphenyl)sulfonylthiomorpholine-3-carboxamide	261911: Inhibition of MMP1	ic50	0.0010	uM
(3S)-N-hydroxy-6-(methoxymethoxy)-4-(4-methoxyphenyl)sulfonyl-2,2-dimethyl-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0010	uM
2-[ethoxy-(4-fluorophenyl)phosphoryl]-N-hydroxy-3,4-dihydro-1H-isoquinoline-3-carboxamide	108920: Inhibitory activity against matrix metalloprotease-1 (MMP-1)(recombinant human collagenase-1).	ki	0.0010	uM
(2S,11S,12R)-7-(4-aminophenyl)sulfonyl-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(2S,11S,12R)-11-N-hydroxy-2-N-methyl-12-(2-methylpropyl)-13-oxo-1,7-diazacyclotridecane-2,11-dicarboxamide;hydrochloride	104564: Inhibition of MMP-1 (human fibroblast collagenase)	ki	0.0010	uM
(2S,3R)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-3-(hydroxymethyl)-2-(4-methoxyphenyl)butanediamide	264663: Binding affinity to recombinant MMP1	ki	0.0010	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(quinolin-8-ylsulfonylamino)butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0011	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(1H-indol-3-yl)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide	104923: In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA	ic50	0.0011	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-prop-2-enylbutanediamide	1727020: Inhibition of PMA-induced human skin fibroblast derived MMP1 by fluorometric assay	ic50	0.0011	uM
(3R,9aS)-N-hydroxy-2-(4-methoxyphenyl)sulfonyl-5-oxo-3,4,7,8,9,9a-hexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-3-carboxamide	108752: Inhibition of human Matrix metalloprotease-1	ic50	0.0012	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-(quinolin-6-ylsulfonylamino)butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0012	uM
(3S)-4-(4-bromophenyl)sulfonyl-N-hydroxy-2,2-dimethyl-1,1-dioxo-1,4-thiazepane-3-carboxamide	108733: In vitro inhibitory activity against truncated collagenase-1 (matrix metalloprotease-1).	ic50	0.0012	uM
(6S,7R,10S)-6-N-hydroxy-10-N-methyl-7-(2-methylpropyl)-8-oxo-2-oxa-9-azabicyclo[10.2.2]hexadeca-1(14),12,15-triene-6,10-dicarboxamide	108935: In vitro inhibition of human MMP-1.	ki	0.0012	uM
(2S,3R)-N-hydroxy-N’-[(2S)-1-(1H-indol-3-yl)-3,3-dimethyl-1-oxobutan-2-yl]-3-(2-methylpropyl)-2-prop-2-enylbutanediamide	104923: In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA	ic50	0.0012	uM
(2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N’-hydroxy-2-(2-methylpropyl)-3-[(4-oxo-3H-quinazolin-6-yl)sulfonylamino]butanediamide	108749: Inhibitory activity against MMP-1 (Matrix metalloprotease-1)	ic50	0.0013	uM
(2S,3R)-N-hydroxy-2-methyl-N’-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)butanediamide	108735: Inhibition of matrix metalloprotease-1 (MMP-1)	ic50	0.0013	uM

CTD chemical–gene interactions

316 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	increases abundance, affects cotreatment, increases activity, affects response to substance, increases expression (+6 more)	28
sodium arsenite	affects expression, decreases expression, affects cotreatment, increases abundance, increases expression (+1 more)	14
Tobacco Smoke Pollution	decreases reaction, increases expression, affects reaction, affects expression, decreases secretion (+1 more)	13
Tetrachlorodibenzodioxin	increases reaction, affects reaction, affects binding, decreases reaction, increases expression (+1 more)	12
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	increases expression, increases secretion, decreases activity, decreases expression, decreases reaction (+1 more)	9
Estradiol	affects cotreatment, decreases expression, affects binding, increases reaction, decreases reaction (+1 more)	8
Vehicle Emissions	decreases reaction, increases expression, increases reaction, affects binding, increases secretion (+3 more)	7
Air Pollutants	decreases reaction, increases abundance, increases expression, decreases expression, increases secretion	6
Benzo(a)pyrene	affects methylation, increases expression	6
Lipopolysaccharides	decreases reaction, increases secretion, increases reaction, affects reaction, affects response to substance (+3 more)	6
U 0126	decreases reaction, increases expression, increases secretion, decreases expression, increases reaction	5
(+)-JQ1 compound	affects cotreatment, decreases expression	5
Acetylcysteine	increases activity, increases expression, decreases reaction, increases abundance	5
Hydrogen Peroxide	decreases reaction, increases expression, affects expression, decreases expression	5
Quercetin	decreases reaction, increases expression, increases secretion, decreases expression	5
Silicon Dioxide	increases expression, increases reaction	5
cobaltiprotoporphyrin	decreases reaction, increases expression, decreases expression, increases reaction	4
Resveratrol	decreases reaction, increases activity, increases expression, increases secretion	4
Plant Extracts	increases abundance, decreases reaction, increases expression, decreases expression	4
Smoke	decreases nitrosation, increases expression, increases secretion	4
Tetradecanoylphorbol Acetate	increases expression, increases reaction, decreases reaction	4
Cyclosporine	increases expression, decreases expression	4
Cadmium Chloride	decreases expression, decreases reaction, increases expression, increases secretion	4
Simvastatin	decreases reaction, increases expression, increases secretion, decreases expression, decreases secretion	4
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	increases expression, increases secretion, increases reaction, decreases reaction	3
SB 203580	decreases reaction, increases activity, increases expression	3
pyrazolanthrone	increases activity, increases expression, decreases reaction	3
2,2’,4,4’-tetrabromodiphenyl ether	increases secretion, increases expression	3
Arsenic Trioxide	affects cotreatment, decreases activity, decreases expression, decreases secretion, decreases reaction (+3 more)	3
Dexamethasone	decreases reaction, increases expression, decreases expression, decreases secretion	3

ChEMBL screening assays

588 unique, capped per target: 574 binding, 10 admet, 3 functional, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4481593	Binding	Inhibition of collagenase (unknown origin) at 200 uM relative to control	Deleting a Chromatin Remodeling Gene Increases the Diversity of Secondary Metabolites Produced by Colletotrichum higginsianum. — *J Nat Prod*
CHEMBL663111	Functional	In vitro antagonist activity against collagenase induced gel-filtered platelet (GFP) aggregation at 50 uM; NA=Inactive	Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. — *J Med Chem*
CHEMBL3868398	ADMET	Inhibition of recombinant human AMPA-activated MMP1 using Cy3-PLGLK(Cy5Q)AR-NH2 as substrate measured after 40 mins by spectrofluorimetric method	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. — *Bioorg Med Chem*

Cellosaurus cell lines

6 cell lines: 5 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_AB52	BHK-MMP1	Spontaneously immortalized cell line	Male
CVCL_B8KL	Abcam HCT 116 MMP1 KO	Cancer cell line	Male
CVCL_B8YX	Abcam MCF-7 MMP1 KO	Cancer cell line	Female
CVCL_B9MU	Abcam A-549 MMP1 KO	Cancer cell line	Male
CVCL_E0I7	Ubigene HeLa MMP1 KO	Cancer cell line	Female
CVCL_F1P4	HyCyte HCT 116 KO-hMMP1	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT07717736	Phase 4	NOT_YET_RECRUITING	Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds
NCT00106821	Phase 4	COMPLETED	Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease
NCT00115492	Phase 4	COMPLETED	Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
NCT00132860	Phase 4	UNKNOWN	Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)
NCT00139932	Phase 4	COMPLETED	Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
NCT00144196	Phase 4	COMPLETED	12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
NCT00144911	Phase 4	COMPLETED	ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
NCT00152984	Phase 4	COMPLETED	Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
NCT00153075	Phase 4	COMPLETED	Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00181207	Phase 4	COMPLETED	Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
NCT00184977	Phase 4	COMPLETED	COPD on Primary Care Treatment (COOPT)
NCT00239408	Phase 4	COMPLETED	Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
NCT00239421	Phase 4	COMPLETED	A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239499	Phase 4	COMPLETED	Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00267917	Phase 4	COMPLETED	Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
NCT00274079	Phase 4	COMPLETED	SPIRIVA in Ususal Care
NCT00291460	Phase 4	UNKNOWN	Inspiratory Muscle Training in Hypercapnic COPD
NCT00346749	Phase 4	TERMINATED	ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.
NCT00351676	Phase 4	COMPLETED	Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment
NCT00355342	Phase 4	COMPLETED	Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
NCT00358358	Phase 4	COMPLETED	Chronic Obstructive Pulmonary Disease Endpoints Study
NCT00359788	Phase 4	COMPLETED	A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.
NCT00361959	Phase 4	COMPLETED	SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
NCT00388882	Phase 4	COMPLETED	Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
NCT00394485	Phase 4	TERMINATED	Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients
NCT00412204	Phase 4	COMPLETED	Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise
NCT00440245	Phase 4	COMPLETED	Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
NCT00523991	Phase 4	COMPLETED	Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
NCT00525512	Phase 4	COMPLETED	Tiotropium In Exercise
NCT00527826	Phase 4	COMPLETED	Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
NCT00530842	Phase 4	COMPLETED	Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
NCT00563381	Phase 4	COMPLETED	Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
NCT00569270	Phase 4	COMPLETED	Dynamic Hyperinflation and Tiotropium
NCT00578968	Phase 4	COMPLETED	Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
NCT00592033	Phase 4	COMPLETED	Effect of Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise
NCT00633217	Phase 4	COMPLETED	Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
NCT00633776	Phase 4	WITHDRAWN	Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)
NCT00667797	Phase 4	COMPLETED	Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
NCT00680056	Phase 4	COMPLETED	Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
NCT00680641	Phase 4	UNKNOWN	Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)
NCT00720226	Phase 4	COMPLETED	Efficacy of Losartan in Preventing Progression of COPD
NCT00730067	Phase 4	WITHDRAWN	Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension
NCT00731770	Phase 4	COMPLETED	Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep
NCT00773786	Phase 4	COMPLETED	Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
NCT00784550	Phase 4	COMPLETED	A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
NCT00857766	Phase 4	COMPLETED	A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00860938	Phase 4	COMPLETED	Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD
NCT00862641	Phase 4	COMPLETED	A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
NCT00911651	Phase 4	COMPLETED	Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00921921	Phase 4	COMPLETED	Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?
NCT00952861	Phase 4	WITHDRAWN	Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)
NCT00962455	Phase 4	COMPLETED	Feedback Reports and e-Learning in Primary Care Spirometry
NCT00969605	Phase 4	COMPLETED	Adaptive Support Ventilation in the Weaning of COPD
NCT00969904	Phase 4	COMPLETED	Pilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00975195	Phase 4	COMPLETED	Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
NCT00984659	Phase 4	COMPLETED	Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease
NCT00994552	Phase 4	UNKNOWN	Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure
NCT00995475	Phase 4	COMPLETED	A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
NCT00996697	Phase 4	COMPLETED	Differential Trough Effects of ‘Triple Therapy’ on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)
NCT01055405	Phase 4	COMPLETED	Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for MMP1 across ~30M SureChEMBL compounds — explore on Sugi Predict.